RESUMEN
In recent years, the classic paradigm of Th1/Th2 CD4(+) T cell-mediated immunity has evolved to include the IL-17A-producing Th17 subset, a distinct proinflammatory CD4(+) T cell lineage. Accumulating evidence suggests that IL-17A and the Th17 pathway may play an important role in the pathology of psoriasis and in other immune-mediated inflammatory diseases. This review summarizes the preclinical and clinical evidence implicating Th17 cells in psoriasis and the therapeutic approaches, approved or under investigation, to target this pathway in psoriasis.
Asunto(s)
Psoriasis/inmunología , Psoriasis/metabolismo , Transducción de Señal , Células Th17/inmunología , Células Th17/metabolismo , Animales , Humanos , Factores Inmunológicos/farmacología , Factores Inmunológicos/uso terapéutico , Terapia Molecular Dirigida , Psoriasis/tratamiento farmacológico , Transducción de Señal/efectos de los fármacos , Células Th17/efectos de los fármacosRESUMEN
Abediterol is a novel potent, long-acting inhaled ß(2)-adrenoceptor agonist in development for the treatment of asthma and chronic obstructive pulmonary disease. Abediterol shows subnanomolar affinity for the human ß(2)-adrenoceptor and a functional selectivity over ß(1)-adrenoceptors higher than that of formoterol and indacaterol in both a cellular model with overexpressed human receptors and isolated guinea pig tissue. Abediterol is a full agonist at the human ß(2)-adrenoceptor (E(max) = 91 ± 5% of the maximal effect of isoprenaline). The potency and onset of action that abediterol shows in isolated human bronchi (EC(50) = 1.9 ± 0.4 nM; t½ onset = 7-10 min) is not significantly different from that of formoterol, but its duration of action (t½ â¼ 690 min) is similar to that of indacaterol. Nebulized abediterol inhibits acetylcholine-induced bronchoconstriction in guinea pigs in a concentration-dependent manner, with higher potency and longer duration of action (t½ = 36 h) than salmeterol (t½ = 6 h) and formoterol (t½ = 4 h) and similar duration of action to indacaterol up to 48 h. In dogs, the bronchoprotective effect of abediterol is more sustained than that of salmeterol and indacaterol at doses without effects on heart rate, thus showing a greater safety margin (defined as the ratio of dose increasing heart rate by 5% and dose inhibiting bronchospasm by 50%) than salmeterol, formoterol, and indacaterol (5.6 versus 3.3, 2.2, and 0.3, respectively). In conclusion, our results suggest that abediterol has a preclinical profile for once-daily dosing in humans together with a fast onset of action and a favorable cardiovascular safety profile.
Asunto(s)
Agonistas de Receptores Adrenérgicos beta 2/farmacología , Broncodilatadores/farmacología , Receptores Adrenérgicos beta 2/metabolismo , Albuterol/análogos & derivados , Albuterol/farmacología , Animales , Asma/tratamiento farmacológico , Asma/metabolismo , Bronquios/efectos de los fármacos , Bronquios/metabolismo , Broncoconstricción/efectos de los fármacos , Perros , Relación Dosis-Respuesta a Droga , Etanolaminas/farmacología , Fumarato de Formoterol , Cobayas , Humanos , Masculino , Monocitos/efectos de los fármacos , Monocitos/patología , Quinolonas/farmacología , Xinafoato de SalmeterolRESUMEN
The synthesis of diverse functionalized ureas in a semi-parallel fashion is described, as well as their ß(1)/ß(2)-adrenergic activities and the corresponding structure-activity relationship (SAR). We have focused on lipophilicity and duration of action, and we have discovered a strong correlation in this series of molecules. A quantitative structure-activity relationship (QSAR) analysis will be presented that quantifies this relationship.
Asunto(s)
Descubrimiento de Drogas , Fenol/síntesis química , Urea/síntesis química , Agonistas de Receptores Adrenérgicos beta 2 , Estructura Molecular , Fenol/química , Fenol/farmacología , Relación Estructura-Actividad Cuantitativa , Urea/química , Urea/farmacologíaRESUMEN
The loss of intracellular potassium is a pivotal step in the induction of apoptosis but the mechanisms underlying this response are poorly understood. Here we report caspase-dependent stimulation of potassium channels by the Fas receptor in a human Jurkat T cell line. Receptor activation with Fas ligand for 30 min increased the amplitude of voltage-activated potassium currents 2-fold on average. This produces a sustained outward current, approximately 10 pA, at physiological membrane potentials during Fas ligand-induced apoptosis. Both basal and Fas ligand-induced currents were blocked completely by toxins that selectively inhibit Kv1.3 potassium channels. Kv1.3 stimulation required the expression of Fas-associated death domain protein and activation of caspase 8, but did not require activation of caspase 3 or protein synthesis. Furthermore, Kv1.3 stimulation by Fas ligand was prevented by chronic stimulation of protein kinase C with 20 nm phorbol 12-myristate 13-acetate during Fas ligand treatment, which also blocks apoptosis. Thus, Fas ligand increases Kv1.3 channel activity through the same canonical apoptotic signaling cascade that is required for potassium efflux, cell shrinkage, and apoptosis.
Asunto(s)
Apoptosis , Proteínas de Arabidopsis , Canales de Potasio con Entrada de Voltaje , Canales de Potasio/metabolismo , Western Blotting , Caspasa 3 , Caspasa 8 , Caspasa 9 , Caspasas/metabolismo , Separación Celular , Electrofisiología , Activación Enzimática , Inhibidores Enzimáticos/farmacología , Proteína Ligando Fas , Ácido Graso Desaturasas/metabolismo , Citometría de Flujo , Humanos , Iones , Células Jurkat , Canal de Potasio Kv1.3 , Glicoproteínas de Membrana/metabolismo , Potenciales de la Membrana , Potasio/metabolismo , Canales de Potasio/química , Propidio/farmacología , Proteína Quinasa C/metabolismo , Estructura Terciaria de Proteína , Transducción de Señal , Acetato de Tetradecanoilforbol/farmacología , Factores de TiempoRESUMEN
Apoptosis is a physiological form of death in which cells turn-on an intrinsic genetic program that eventually leads to their destruction in a highly regulated manner. This process renders elimination of "unwanted cells" in the body, and accounts for cellular turnover and homeostasis of tissues in multicellular organisms. Consequently, an imbalance in the apoptotic rate in a particular tissue can lead to profound effects in the whole organism. Exposure of cells to apoptotic stimuli induces a rapid loss of cell volume (apoptotic volume decrease) that plays a pivotal role in the decision of a cell to undergo apoptosis. Interestingly, the apoptotic volume decrease is driven by changes in ionic fluxes across the plasma membrane that promote a decrease in the intracellular ions that ultimately also leads to a reduction in intracellular ionic strength. Despite an intensive research effort however, the cellular and molecular mechanisms that trigger changes in cell volume during apoptosis remain poorly understood. Nevertheless, this apoptotic volume decrease has been shown to be a necessary component of the apoptotic cascade and an important point of modulation for the entire cell death process. In this review, we will focus on the importance of the apoptotic volume decrease in the context of signaling and modulation of programmed cell death.